Skip to content

Clinical Application of BioCleanse Meniscus

Clinical Application of BioCleanse Meniscus Registry

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00659880
Acronym
Meniscus
Enrollment
9
Registered
2008-04-16
Start date
2008-04-30
Completion date
2015-07-31
Last updated
2017-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tear of Meniscus of Knee

Keywords

Meniscus transplant, Meniscal allograft, MAT, Knee

Brief summary

This study will follow patients after routine surgery of a meniscal allograft transplant.

Detailed description

The BioCleanse meniscus is available to to all orthopedic surgeons for transplantation. The purpose of this registry is to allow close monitoring of a subgroup of patients receiving the BioCleanse Meniscus. All patients who have selected a BioCleanse Meniscus for their Meniscal Allograft transplant will be asked to join the registry. Outcomes will be measured by subjective subject questionnaires as well as X-rays and MRI.

Interventions

OTHERBioCleanse Meniscus

Subjects will undergo routine meniscal allograft transplant surgery.

Sponsors

RTI Surgical
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* All patients, up to 10 who have selected a BioCleanse Meniscus transplant

Exclusion criteria

* Anyone not eligible for a meniscal transplant

Design outcomes

Primary

MeasureTime frameDescription
Knee Injury and Osteoarthritis Outcome Score (KOOS)60 monthsThe score is an index score from 0 to 100, with 0 representing extreme problems and 100 representing no problems.

Secondary

MeasureTime frameDescription
MRI Assessments12 monthsMRI images were assessed for integration of the meniscal allograft transplant for integration of the anterior horn, body and posterior horn. Images were also assessed for oedema in each of these 3 regions of the meniscus.

Countries

United States

Participant flow

Participants by arm

ArmCount
Meniscal Allograft Transplant
Patients who received a BioCeanse Meniscal Allograft Transplant
9
Total9

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up5

Baseline characteristics

CharacteristicMeniscal Allograft Transplant
Age, Continuous31.7 years
STANDARD_DEVIATION 7.6
Region of Enrollment
United States
9 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
4 / 9
serious
Total, serious adverse events
0 / 9

Outcome results

Primary

Knee Injury and Osteoarthritis Outcome Score (KOOS)

The score is an index score from 0 to 100, with 0 representing extreme problems and 100 representing no problems.

Time frame: 60 months

ArmMeasureValue (MEAN)Dispersion
Meniscal Allograft TransplantKnee Injury and Osteoarthritis Outcome Score (KOOS)70.1 units on a scaleStandard Deviation 33.6
p-value: 0.06Friedman
Secondary

MRI Assessments

MRI images were assessed for integration of the meniscal allograft transplant for integration of the anterior horn, body and posterior horn. Images were also assessed for oedema in each of these 3 regions of the meniscus.

Time frame: 12 months

ArmMeasureGroupValue (NUMBER)
Meniscal Allograft TransplantMRI AssessmentsIntegration of Meniscal Body4 participants
Meniscal Allograft TransplantMRI AssessmentsIntegration of Anterior Horn3 participants
Meniscal Allograft TransplantMRI AssessmentsIntegration of Posterior Horn4 participants
Meniscal Allograft TransplantMRI AssessmentsMild Edema Anterior Horn2 participants
Meniscal Allograft TransplantMRI AssessmentsMild Edema Posterior Horn1 participants
Meniscal Allograft TransplantMRI AssessmentsMild Edema Meniscal Body0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026